文献速递免疫规划卫生政策与健康促进

十个登革热流行国家登革热疫苗接种的成本效果分析

Cost-effectiveness of dengue vaccination in ten endemic countries.
PubMed 文献 · Vaccine · 2017-12-08

基于两项在10个国家或地区开展的3期临床试验结果,利用已发表的数学模型评估登革热疫苗在拉丁美洲和亚洲试验点相似人群中的成本效果。主要场景为30年时间跨度、80%覆盖率、9岁起接种3剂常规疫苗(每剂20美元),可辅以4年或8年队列补种。常规接种使拉丁美洲国家年人均直接和间接疾病成本降低22%(从10.51美元降至8.17美元),亚洲国家降低23%(从5.78美元降至4.44美元)。卫生系统视角下,五个拉丁美洲国家平均ICER为4216美元/DALY(波多黎各666美元/DALY至墨西哥5865美元/DALY),五个亚洲国家平均ICER为3751美元/DALY(马来西亚1935美元/DALY至菲律宾5101美元/DALY)。

要点

  • 常规接种使拉丁美洲国家年人均疾病成本降低22%(10.51→8.17美元),亚洲国家降低23%(5.78→4.44美元)
  • 卫生系统视角下,七个国家ICER低于人均GDP一倍(高度成本效果),其余三个国家ICER为人均GDP的1-3倍(有成本效果)
  • 社会视角下,三个国家常规接种可节省成本;纳入补种活动后ICER相似

核心结论

  • 该疫苗在与试验点相似的地点可能具有有利的经济价值。

研究设计与样本

  • 利用已发表的数学模型,评估登革热疫苗在拉丁美洲和亚洲10个国家或地区试验点相似人群中的成本效果。
  • 主要场景为30年时间跨度、80%覆盖率、9岁起接种3剂常规疫苗(每剂20美元),可辅以4年或8年队列补种。
  • 疾病成本、登革热死亡率、疫苗损耗和疫苗接种管理成本取自文献。

主要发现

  • 常规接种使拉丁美洲国家年人均直接和间接疾病成本降低22%(从10.51美元降至8.17美元)。
  • 常规接种使亚洲国家年人均直接和间接疾病成本降低23%(从5.78美元降至4.44美元)。
  • 卫生系统视角下,五个拉丁美洲国家平均ICER为4216美元/DALY(范围:波多黎各666美元/DALY至墨西哥5865美元/DALY)。
  • 卫生系统视角下,五个亚洲国家平均ICER为3751美元/DALY(范围:马来西亚1935美元/DALY至菲律宾5101美元/DALY)。
  • 社会视角下,三个国家常规接种可节省成本;纳入补种活动后ICER相似。

关键数值与推荐

  • 卫生系统视角下,七个国家ICER低于人均GDP一倍,为高度成本效果。
  • 卫生系统视角下,其余三个国家ICER为人均GDP的1-3倍,为有成本效果。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Following publication of results from two phase-3 clinical trials in 10 countries or territories, endemic countries began licensing the first dengue vaccine in 2015. Using a published mathematical model, we evaluated the cost-effectiveness of dengue vaccination in populations similar to those at the trial sites in those same Latin American and Asian countries. Our main scenarios (30-year horizon, 80% coverage) entailed 3-dose routine vaccinations costing US$20/dose beginning at age 9, potentially supplemented by catch-up programs of 4- or 8-year cohorts. We obtained illness costs per case, dengue mortality, vaccine wastage, and vaccine administration costs from the literature. We estimated that routine vaccination would reduce yearly direct and indirect illness cost per capita by 22% (from US$10.51 to US$8.17) in the Latin American countries and by 23% (from US$5.78 to US$4.44) in the Asian countries. Using a health system perspective, the incremental cost-effectiveness ratio (ICER) averaged US$4,216/disability-adjusted life year (DALY) averted in the five Latin American countries (range: US$666/DALY in Puerto Rico to US$5,865/DALY in Mexico). In the five Asian countries, the ICER averaged US$3,751/DALY (range: US$1,935/DALY in Malaysia to US$5,101/DALY in the Philippines). From a health system perspective, the vaccine proved to be highly cost effective (ICER under one times the per capita GDP) in seven countries and cost effective (ICER 1-3 times the per capita GDP) in the remaining three countries. From a societal perspective, routine vaccination proved cost-saving in three countries. Including catch-up campaigns gave similar ICERs. Thus, this vaccine could have a favorable economic value in sites similar to those in the trials.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Zeng W, Halasa-Rappel YA, Baurin N, et al. Cost-effectiveness of dengue vaccination in ten endemic countries. Vaccine. 2017. PMID: 29229427. doi:10.1016/j.vaccine.2017.11.064

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。